Search Results - "Kragballe, K."

Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris by Gniadecki, R., Kragballe, K., Dam, T.N., Skov, L.

“…Summary Background  Adherence to treatment is an indicator of treatment success. Long‐term data on adherence to biologic treatment in psoriasis are lacking…”
Get full text

Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin by Johansen, C., Usher, P.A., Kjellerup, R.B., Lundsgaard, D., Iversen, L., Kragballe, K.

“…Summary Background  Th17 cells are a lineage of proinflammatory T helper cells producing interleukin (IL)‐17. The importance of Th17 cells in inflammation and…”
Get full text

A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis by Mrowietz, U., de Jong, E.M.G.J., Kragballe, K., Langley, R., Nast, A., Puig, L., Reich, K., Schmitt, J., Warren, R.B.

“…Background There is limited information on systemic and biological treatment optimization and transitioning in routine clinical practice. Objective To provide…”
Get full text

Aldara®-induced skin inflammation: studies of patients with psoriasis by Vinter, H., Iversen, L., Steiniche, T., Kragballe, K., Johansen, C.

“…Summary Background The application of Aldara® cream containing 5% imiquimod stimulates Toll‐like receptor 7/8 on plasmacytoid dendritic cells, thereby…”
Get full text

Definition of treatment goals for moderate to severe psoriasis: a European consensus by Mrowietz, U, Kragballe, K, Reich, K, Spuls, P, Griffiths, C. E. M, Nast, A, Franke, J, Antoniou, C, Arenberger, P, Balieva, F, Bylaite, M, Correia, O, Daudén, E, Gisondi, P, Iversen, L, Kemény, L, Lahfa, M, Nijsten, T, Rantanen, T, Reich, A, Rosenbach, T, Segaert, S, Smith, C, Talme, T, Volc-Platzer, B, Yawalkar, N

“…Patients with moderate to severe psoriasis are undertreated. To solve this persistent problem, the consensus programme was performed to define goals for…”
Get full text

Tumour necrosis factor-α plays a significant role in the Aldara-induced skin inflammation in mice by Vinter, H., Kragballe, K., Steiniche, T., Gaestel, M., Iversen, L., Johansen, C.

“…Summary Background Recently, the Aldara‐induced psoriasis‐like skin inflammation model in mice has attracted increased attention, due to its dependence on the…”
Get full text

Pooled safety analysis of calcipotriol plus betamethasone dipropionate gel for the treatment of psoriasis on the body and scalp by Kragballe, K., van de Kerkhof, P.

“…The fixed combination calcipotriol plus betamethasone dipropionate gel is a first‐line treatment for psoriasis vulgaris. The objective was to perform a…”
Get full text

Strategies for improving the quality of care in psoriasis with the use of treatment goals - a report on an implementation meeting by Mrowietz, U, Kragballe, K, Nast, A, Reich, K

“…Targeted treatment, early intervention and the use of treatment goals is a new approach in medicine that has been implemented across several disciplines (e.g…”
Get full text

The mitogen-activated protein kinases p38 and ERK1/2 are increased in lesional psoriatic skin by Johansen, C., Kragballe, K., Westergaard, M., Henningsen, J., Kristiansen, K., Iversen, L.

“…Summary Background  Alterations in specific signal transduction pathways may explain the hyperproliferation and abnormal differentiation of the keratinocytes…”
Get full text

Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study by Daudén, E, Griffiths, CEM, Ortonne, J-P, Kragballe, K, Molta, CT, Robertson, D, Pedersen, R, Estojak, J, Boggs, R

“…To assess patient-reported outcomes (PRO) in patients with moderate-to-severe plaque psoriasis receiving continuous or paused etanercept treatment. In a…”
Get full text

Preferential inhibition of the mRNA expression of p38 mitogen-activated protein kinase regulated cytokines in psoriatic skin by anti-TNFα therapy by Johansen, C., Vinter, H., Soegaard-Madsen, L., Olsen, L.R., Steiniche, T., Iversen, L., Kragballe, K.

“…Summary Background  Anti‐TNFα therapies are well established for severe psoriasis; however, their mechanism of action in disease resolution is not fully…”
Get full text

Topical corticosteroids in psoriasis: strategies for improving safety by Horn, EJ, Domm, S, Katz, HI, Lebwohl, M, Mrowietz, U, Kragballe, K

“…Corticosteroids are a mainstay of topical therapy for psoriasis. While efficacious and relatively safe when used carefully, the potential for side effects,…”
Get full text

A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet®/Daivobet®/Taclonex®) in the treatment of psoriasis vulgaris by Kragballe, K., Austad, J., Barnes, L., Bibby, A., De La Brassinne, M., Cambazard, F., Fleming, C., Heikkilä, H., Jolliffe, D., Peyri, J., Svensson, Å., Toole, J., Wozel, G.

“…Summary Background  The calcipotriol/betamethasone dipropionate two‐compound product Dovobet®/Daivobet®/Taclonex®(LEO Pharma A/S, Ballerup, Denmark) has been…”
Get full text

Barriers to the prescription of systemic therapies for moderate-to-severe psoriasis––a multinational cross-sectional study by Nast, A., Mrowietz, U., Kragballe, K., de Jong, E. M. G. J., Puig, L., Reich, K., Warren, R. B., Werner, R., Kopkow, C., Schmitt, J.

“…Despite the availability of a plethora of approved systemic treatments, high proportions of patients with moderate-to-severe psoriasis do not receive systemic…”
Get full text

A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study by Thaçi, D., Ortonne, J.-P., Chimenti, S., Ghislain, P.-D., Arenberger, P., Kragballe, K., Saurat, J.-H., Khemis, A., Sprøgel, P., Esslinger, H.-U., Unnebrink, K., Kupper, H.

“…Summary Background  Data are lacking on the use of topical therapies in combination with tumour necrosis factor blockers for the treatment of psoriasis…”
Get full text

The expression of dual-specificity phosphatase 1 mRNA is downregulated in lesional psoriatic skin by Kjellerup, R.B., Johansen, C., Kragballe, K., Iversen, L.

“…Summary Background  The p38 mitogen‐activated protein kinase (MAPK) plays an important role in inflammatory processes and displays increased activity in…”
Get full text

Quality of life and patient benefit following transition from methotrexate to ustekinumab in psoriasis by Augustin, M., Blome, C., Paul, C., Puig, L., Luger, T., Lambert, J., Chimenti, S., Girolomoni, G., Kragballe, K., Naessens, D., Bergmans, P., Smirnov, P., Barker, J., Reich, K.

“…Background TRANSIT (NCT01059773) compared immediate and gradual transition from methotrexate to ustekinumab in psoriasis patients via multiple measures,…”
Get full text

A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet((R))/Daivobet((R))/Taclonex((R))) in the treatment of psoriasis vulgaris by Kragballe, K, Austad, J, Barnes, L, Bibby, A, de la Brassinne, M, Cambazard, F, Fleming, C, Heikkila, H, Jolliffe, D, Peyri, J, Svensson, Åke, Toole, J, Wozel, G

“…The calcipotriol/betamethasone dipropionate two-compound product Dovobet (R)/Daivobet (R)/Taclonex (R)(LEO Pharma A/S, Ballerup, Denmark) has been shown to be…”
Get full text

Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial by Kragballe, K., Hoffmann, V., Ortonne, J.P., Tan, J., Nordin, P., Segaert, S.

“…Summary Background  Current topical therapies for scalp psoriasis are difficult or unpleasant to apply, resulting in decreased adherence and efficacy…”
Get full text

Adalimumab therapy rapidly inhibits p38 mitogen-activated protein kinase activity in lesional psoriatic skin preceding clinical improvement by Soegaard-Madsen, L., Johansen, C., Iversen, L., Kragballe, K.

“…Summary Background  The pathogenesis of psoriasis and the mechanisms of action of antitumour necrosis factor (TNF)‐α therapies are incompletely understood…”
Get full text